Format

Send to

Choose Destination
Biotechnol Rep (Amst). 2017 May 17;15:24-26. doi: 10.1016/j.btre.2017.05.002. eCollection 2017 Sep.

Dusquetide: Reduction in oral mucositis associated with enduring ancillary benefits in tumor resolution and decreased mortality in head and neck cancer patients.

Author information

1
Radiation Oncology, University of Kentucky, 800 Rose Street, Lexington, KY, 40536, USA.
2
Gibbs Cancer Center, Spartanburg Regional Hospital, 101 E Wood, Spartanburg, SC, 29303, USA.
3
Veteran's Affairs Long Beach Hospital, 5901 E 7th Street, Mail Code 114A, Long Beach, CA, 98022, USA.
4
Department of Medicine, University of Michigan Health System,1500 E Medical Center Drive, Ann Arbor, MI, 48109, USA.
5
Department of Radiation Oncology, Willis-Knighton Cancer Center,2600 Kings Highway, Shreveport, LA, 71103, USA.
6
Division of Hematology and Oncology, Washington University, 660 South Euclid Avenue, Saint Louis, MO, 63110, USA.
7
Department of Hematology and Oncology, Wake Forest Health Sciences Medical Center, 1 Medical Center Blvd., Winston-Salem, NC, 27157, USA.
8
PharPoint Research, 5003 S Miami Blvd #100, Durham, NC, 27703, USA.
9
Oral Medicine and Diagnostic Services, Dana Farber/Harvard Cancer Center, Boston, MA, USA.
10
Biomodels LLC,313 Pleasant Street, Watertown, MA 02472, USA.
11
Soligenix Inc., 29 Emmons Drive, Suite C-10, Princeton, NJ, 08540, USA.

Abstract

Innate immunity is a key component in the pathogenesis of oral mucositis, a universal toxicity of chemoradiation therapy (CRT). Dusquetide, a novel Innate Defense Regulator, has demonstrated both nonclinical and clinical efficacy in ameliorating severe oral mucositis (SOM). Long term follow-up studies from the Phase 2 clinical study evaluating dusquetide as a treatment for SOM in head and neck cancer (HNC) patients receiving CRT have now been completed. Extended analysis indicates that dusquetide therapy was well-tolerated and did not contribute to increased infection, tumor growth or mortality. Potential ancillary benefits of duquetide therapy were also identified.

KEYWORDS:

CRT, chemoradiation therapy; Cancer supportive care; Dusquetide; HNC, head and neck cancer; Head and neck cancer; IDR, innate defense regulator; Immune; Innate; OM, oral mucositis; Oral mucositis; SOM, severe oral mucositis

Supplemental Content

Full text links

Icon for PubMed Central
Loading ...
Support Center